To discover novel antiviral agents, based on the high
antiviral
activity of (4-oxo-4H-quinolin-1-yl)-acetic acid
hydrazide (C), a series of 4-oxo-4H-quinoline
acylhydrazone derivatives were designed, synthesized, and first evaluated
for their antiviral and fungicidal activities. Most acylhydrazone
derivatives exhibited moderate to good antiviral activities in vivo.
The inactive, curative, and protective activities of compounds 4 (51.2, 47.6, and 46.3%), 11 (49.6, 43.0, and
45.2% at 500 mg/L), and 17 (47.1, 49.2, and 44.1%) were
higher than those of ribavirin (39.2, 38.0, and 40.8%) at 500 mg/L.
Molecular docking showed that compound 4 exhibited a
stronger affinity to TMV coat protein (TMV-CP) than ribavirin, with
a binding energy (−6.89 kcal/mol) slightly lower than that
of ribavirin (−6.08 kcal/mol). Microscale thermophoresis showed
that compound 4 (K
d = 0.142
± 0.060 μM) exhibited a strong binding ability to TMV-CP,
superior to that of ribavirin (K
d = 0.512
± 0.257 μM). The results of transmission electron microscopy
showed that compound 4 hindered the self-assembly and
growth of TMV. The antifungal activities of most compounds were moderate
at 50 mg/L, among which compounds 12 and 21 exhibited a 72.1 and 76.5% inhibitory rate against Physalospora piricola, respectively. Meanwhile, compound 16 exhibited a 60% inhibitory rate against Cercospora arachidicola Hori at 50 mg/L.